Compare Mesoblast Limited (MESO) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Schlumberger NV — how do they compare? Mesoblast Limited trades at $14.29 (market cap $1.75B), while Schlumberger NV trades at $48.95 (market cap $72.69B). The key difference: Schlumberger NV is far larger — about 41.5× Mesoblast Limited's market cap, and Schlumberger NV pays a 2.41% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Schlumberger NV for 99 Days on average.
| MESO | SLB | |
|---|---|---|
Market Cap | $1.75B | $72.69B |
Volume | 239,027 | 16,228,451 |
Sector | Health | Energy |
52-Week High | $20.96 | $60.10 |
52-Week Low | $13.19 | $31.72 |
Typical Hold Time | 15 Days | 99 Days |
Enterprise Value | $1.83B | $81.42B |
Dividend Yield | — | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.75, down 1.36% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $102.14 million in 2025, though revenue grew to $120 million in 2026. Recent milestones include FDA approval for a new potency assay and completion of a Phase 3 trial for chronic low back pain, signaling progress in its commercial pipeline.
The outlook is mixed; analyst consensus leans buy (45% buy ratings), but profitability remains a challenge with negative margins. Key risks include high cash burn and competitive pressures, while catalysts hinge on successful commercialization of RYONCIL and upcoming trial results. The stock presents a high-risk, high-reward opportunity in the biotech sector.
SLB trades at $48.98, up 2.13% today, with strong analyst support (85% buy ratings) and a $64.58 consensus price target suggesting 32% upside. Recent contract wins in Saudi Arabia, Oman, and Mozambique expand revenue visibility, though technical indicators show bearish momentum. The company maintains solid profitability with 8.53% net margins and consistent earnings beats in recent quarters.
SLB's multi-year contracts provide stable revenue streams, but declining profit margins and bearish technicals present near-term headwinds. The stock offers value with reasonable valuation multiples (P/E 23.89) and dividend income, though energy sector volatility and execution risks on new projects require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
